entertainment -WSS

entertainment

author：entertainment 2025-10-02 00:41:35 - browse：221

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

Wikipedia

entertainment

WSS

Medical experts exlpore how to eliminate bias in clinical algorithms

Heart disease and mental health: A look at cardiac psychology

Supreme Court strikes down Biden student loan forgiveness program

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Bright Health sells Medicare Advantage business to Molina

Supreme Court strikes down Biden student loan forgiveness program

Affirmative action in medical school literally saved lives

GSK to buy asthma

Apple is now the first public company to be valued at $3 trillion

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Trump demands the U.S. pay no more for drugs than other countries … again

The strange history of BMI, the body mass index

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why do we get seasonal allergies?

explore

How I ended up pumping milk in a bathroom stall at JPM 2024

GOP inquiry over gain

Ukrainian soldiers say they owe lives to US

How I ended up pumping milk in a bathroom stall at JPM 2024

The strange history of BMI, the body mass index

New England Journal of Medicine addresses racist history, slavery

Wikipedia

focus

entertainment

leisure time